Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health
This article was originally published in The Gray Sheet
Executive Summary
Rep. Henry Waxman, D-Calif., is challenging FDA's priorities for writing rules and guidances, saying the agency appears to be more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health